trending Medical education topic: Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is caused when the tiny arteries in the lung become thick and narrow, resulting in the heart working harder and less effectively to pump blood throughout the body. 500-1000 new cases of PAH are diagnosed in the United States each year. It is most common in women aged 30-60 and disproportionally affects African American and Hispanic women. Treatments are available to help control symptoms and improve quality of life. Recently, the FDA approved several new medications for pulmonary arterial hypertension, so it is important for healthcare professionals to know about current available options for patients with this disease. 

Proposed Learning Objectives:

At the conclusion of this activity, the learners will be able to:

1. Recognize and diagnose pulmonary arterial hypertension (PAH) early
2. Identify when to refer the patient to the specialist/pulmonary clinic
3. Follow updated guidelines and treatment options for PAH
4. Choose appropriate treatment/medication to treat PAH
5. Assess and identify patients at higher risk of PAH

If your medical staff needs an update on pulmonary arterial hypertension, consider contacting our office to book a speaker at 877-505-4777 or info@speakersnetwork.com.

References:

https://www.lung.org/lung-health-diseases/lung-disease-lookup/pulmonary-arterial-hypertension/learn-about-pulmonary-arterial-hypertension

https://www.medscape.com/viewarticle/fda-oks-sotatercept-pulmonary-arterial-hypertension-2024a10005ug

https://www.prnewswire.com/news-releases/us-fda-approves-opsynvi-macitentan-and-tadalafil-as-the-first-and-only-once-daily-single-tablet-combination-therapy-for-patients-with-pulmonary-arterial-hypertension-pah-302097530.html